Antiplatelet Therapies: Aspirin at the Heart of New Directions

Author(s): Natalia Bunimov, Odette Laneuville

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
Formerly Current Drug Targets - Cardiovascular & Hematological Disorders

Volume 13 , Issue 3 , 2013

Become EABM
Become Reviewer
Call for Editor


When introduced over 100 years ago, aspirin was prescribed as an analgesic drug to arthritic patients for pain relief. The prevalence of users grew quite rapidly and to this day, aspirin remains widely used in clinical practice. The popularity of aspirin resulted not only from its analgesic properties but also from a second benefit recognized later as an anti-platelet effect. It was this important activity of aspirin that made it one of the most recommended drugs for the treatment and prevention of cardiovascular diseases. The anti-platelet effect of aspirin emerged from the first few case reports published in the early 1900s and was described as a mild bleeding. The molecular mechanisms involved were described in 1971 and constituted the irreversible inhibition of cyclooxygenase-1 enzyme and prevention of platelet aggregation. Today, the contribution of aspirin to our understanding of cardiovascular health persists and remains considerable. Observations from large cohorts of aspirin users generate massive amount of valuable information used in the identification of factors influencing the potential risk for cardiovascular diseases, including sex, age and genetic predisposition. Aspirin and the path of discovery leading to its anti-platelet activity has taken a hundred years was based on manifestations of effects observed in its users, and it remains a successful strategy for the identification of new avenues to treat cardiovascular diseases associated with hyper-platelet activity. The contribution of aspirin to the understanding of cardiovascular diseases and to the design of effective treatment and prevention strategies, remains of high importance in our society.

Keywords: Arthritis, aspirin, cardiovascular disease, cyclooxygenase (COX), nonsteroidal anti-inflammatory drugs (NSAIDs), pain, platelet, prostaglandin endoperoxyde H synthase-1 (PTGS1).

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 29 January, 2014
Page: [173 - 184]
Pages: 12
DOI: 10.2174/1871529X1303140129154040
Price: $65

Article Metrics

PDF: 38